Consulting in development and regulatory service to be supported by new appointments.
MDS Pharma Services is expanding its Development & Regulatory Services (DRS) business in Europe. The CRO will offer full-service DRS consulting services to support development of new drugs and biopharmaceutical products for clients in Europe.
The DRS organisation will also be fully integrated with consultants in the US and in Canada to provide product development consulting, program management, and regulatory affairs services.
While European expansion is expected to broaden the company's consulting capabilities in development and regulatory services, according to David Spaight, MDS Pharma Services president, "We will now be able to provide expertise to support our biotechnology and Asian pharmaceutical clients in the process of commercialising their products in North American and European markets."
With the expansion plan, the appointment of two industry experts has been announced: Didier Saur, M.D. as vice president of medical affairs, and Sarah Roberts, Ph.D. as senior director of regulatory affairs.
Based near Paris, France, Dr Saur, with over 20 years' experience as a physician in the pharmaceutical and contract research industry, will lead the MDS Pharma Services product development consulting, program management, and regulatory affairs services in Europe. He will also be responsible for organizing and chairing the medical advisory board for DRS.
Dr Roberts, with more than 10 years' experience as an oncology research specialist is to be based near London and will provide regulatory affairs consulting for clients on European regulatory issues. She has worked with the Dana Farber Cancer Institute in Boston, MA and the Gray Cancer Institute in London, has experience with regulatory agencies in both North America and Europe, and most recently served as a director for Smart Regulatory Solutions Ltd, an independent consulting firm, which she established.
Keywords : Europe, MDS, CRO, Industry news, Lifescience, Services, Consulting, Development, Regulatory, Pharmaceuticals, Biopharmaceuticals,
